Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

<p>Supplemental Figure S1. Mean pharmacokinetic profiles for single agent talazoparib (BMN673 in phase I clinical trial PRP-001) versus combination therapy.</p>

Furkejuvvon:
Bibliográfalaš dieđut
Váldodahkki: Zev A. Wainberg (15047031) (author)
Eará dahkkit: Arun S. Singh (15036660) (author), Gottfried E. Konecny (15047034) (author), Kelly E. McCann (15047037) (author), J. Randolph Hecht (15047040) (author), Jonathan Goldman (15047043) (author), Bartosz Chmielowski (15036666) (author), Richard S. Finn (10431048) (author), Neil O'Brien (15047046) (author), Erika Von Euw (15047049) (author), Megan M. Price (15047052) (author), Diego Martinez (15047055) (author), Lisa Yonemoto (15047058) (author), Meghan Brennan (15047061) (author), John A. Glaspy (15047064) (author), Dennis J. Slamon (15047067) (author)
Almmustuhtton: 2025
Fáttát:
Cancer
Therapeutic Research and Development
Clinical Research and Trials
Methods and Technology
Clinical Trial Results
Phase I clinical trials
Drug Targets
Oncoprotein & tumor suppressor drug targets
Preclinical Models
In vitro models of cancer
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid